Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Abstract: The present disclosure, in some aspects, is directed to methods of designing an oral drug dosage form formulated and configured to have a desired pharmacokinetic profile. In other aspects, the present disclosure is directed to oral drug dosage forms having a desired pharmacokinetic profile, and methods of making, such as three-dimensional printing, such oral drug dosage forms.

Abstract: The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology.

Abstract: A 3D printing device (100), comprising a melt extrusion module (102), a printing module (103), and a platform module (104). The melt extrusion module (102) comprises a processing chamber (121) consisting of a feed inlet (124) and a discharge outlet (125), as well as an extrusion means (122) and a heating means (123) disposed at the processing chamber; the melt extrusion module (102) is configured to receive an initial material from the feed inlet (124) of the processing chamber (121), and heat and extrude the initial material to convert the initial material into a molten body, which is extruded out of the discharge outlet (125) of the processing chamber (121). The printing module (103) is communicated with the discharge outlet (125) of the processing chamber (121) and is provided with a nozzle (131); the printing module (103) is configured to receive the molten body extruded from the discharge outlet (125) of the processing chamber (121) and guide the molten body to be extruded out of the nozzle (131).

Abstract: A dosage form of controlled release at specific gastrointestinal sites is provided. The dosage form includes a shell defining a first and a second compartment, a first active pharmaceutical ingredient (API) loaded in the first compartment, and a second API loaded in the second compartment, wherein the first API and the second API can be the same or different. The shell includes a first material soluble in a first gastrointestinal site and a second material soluble in a second gastrointestinal site.

Abstract: Disclosed are Lactobacillus rhamnosus strain 753 and uses thereof, a silage additive and silage. Lactobacillus rhamnosus strain 753 is deposited in China General Microbiological Culture Collection Center with an accession number of CGMCC 18233. Lactobacillus rhamnosus strain 753 can improve the quality of silage in a high-temperature and high-humidity region, and the silage processed by Lactobacillus rhamnosus strain 753 has good stability and low pH, low aflatoxin B1 content and less dry matter loss. In addition, secondary fermentation can be avoided in the silage processed by Lactobacillus rhamnosus strain 753 when a silo or bale for silage is opened.

Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Abstract: In some aspects, the present disclosure provides dosage forms, such as oral drug dosage forms, configured to provide a desired release profile, the dosage forms comprising a multi-layered structure comprising a plurality of layers of a first erodible material admixed with a compound (e. g., a drug) or a reagent, wherein the first erodible material is embedded in a second material not admixed with the compound (e. g., the drug) or the reagent. In other aspects, the present disclosure provides methods of designing, such as obtaining a thickness and/or surface area of a layer comprising an erodible material admixed with a compound (e. g., a drug) or areagent, and/or amount of the compound (e. g., the drug) or the reagent admixed in the erodible material, and methods of making, such as three-dimensional printing, dosage forms configured to provide desired release profiles.

Abstract: The present disclosure provides oral drug dosage forms comprising: (a) an erodible non-stimulant material admixed with an ADHD non-stimulant; and (b) an erodible stimulant material admixed with an ADHD stimulant, wherein the erodible non-stimulant material admixed with the ADHD non-stimulant is embedded in a substrate material, and wherein upon exposure to gastrointestinal fluid the ADHD non-stimulant is released according to a desired non-stimulant release profile and the ADHD stimulant is released according to a desired stimulant release profile. In some embodiment, the ADHD non-stimulant is released according to a sustained release profile. In some embodiments, the ADHD stimulant is released according to an immediate release profile. The oral drug dosage forms of the present disclosure are useful for the treatment of attention deficit hyperactivity disorder (ADHD). Also provided herein are methods of designing and manufacturing the oral drug dosage forms described herein.

Abstract: A method of manufacturing a tube is provided. The method includes: selecting a core pipe having a thickness that is initially less than a desired thickness of the tube; and building-up an outer layer over an exterior surface of the core pipe via additive manufacturing so as to increase the thickness of the core pipe such that the thickness of the core pipe is equal to the desired thickness of the tube.

Abstract: Provided herein are devices and systems for depositing a material or manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. Further provided are methods of using the devices and systems, as well as methods of manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. In certain embodiments, the device includes a material supply system configured to melt an pressurized a material, a pressure sensor configured to detect a pressure of the material within the device, and a control switch comprising a sealing needle operable in an open position and closed position. The sealing needle extends through a feed channel containing the material and includes a taper end, wherein the tapered end of the sealing needle engages a tapered inner surface of a nozzle to inhibit flow of the material through the nozzle when the sealing needle is in the closed position.

Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Abstract: A liquid crystal display and a backlight module thereof are provided. The backlight module includes a backlight source and a light guide plate. The backlight source is disposed at a side surface of the light guide plate. The light guide plate has an accommodation section for accommodating a functional module. The backlight module includes a compensation light source that is disposed on the light guide plate. The accommodation section is located between the backlight source and the compensation light source. The backlight module includes a compensation light source, and the backlight source and the compensation light source are located at two opposite sides of the accommodation section. The compensation light source may compensate for the illumination light in the light guide plate blocked by the functional module, so as to solve the non-uniform display problem of blocking the illumination light from the backlight source by the functional module.

Abstract: Provided herein are devices and systems for depositing a material or manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. Further provided are methods of using the devices and systems, as well as methods of manufacturing a product, such as a pharmaceutical dosage form, by additive manufacturing. In certain embodiments, the device includes a material supply system configured to melt an pressurized a material, a pressure sensor configured to detect a pressure of the material within the device, and a control switch comprising a sealing needle operable in an open position and closed position. The sealing needle extends through a feed channel containing the material and includes a taper end, wherein the tapered end of the sealing needle engages a tapered inner surface of a nozzle to inhibit flow of the material through the nozzle when the sealing needle is in the closed position.

Abstract: The present invention provides a method for preparing a resveratrol compound, and belongs to the technical field of organic synthesis. In the present invention, first alkoxy-substituted benzyl halide, alkoxy-substituted benzaldehyde and a metal catalyst are subjected to oxidative addition and reduction elimination reactions to obtain alkoxy-substituted diphenylethanone; and then the alkoxy-substituted diphenylethanone and a metal catalyst are subjected to reduction, trans elimination and selective debenzylation reactions under a hydrogen atmosphere to obtain the resveratrol compound. In the preparation method of the present invention, the hydrogenation reduction, trans elimination and selective debenzylation reactions can be achieved just by a one-pot process, where the reaction directly obtains a trans olefin, thereby avoiding the formation of a isomer; and also the reaction selectively catalyzes debenzylation to eliminate Lewis acids from the source, and has the advantage of a high yield.

Abstract: A liquid crystal display and a backlight module thereof are provided. The backlight module includes a backlight source and a light guide plate. The backlight source is disposed at a side surface of the light guide plate. The light guide plate has an accommodation section for accommodating a functional module. The backlight module includes a compensation light source that is disposed on the light guide plate. The accommodation section is located between the backlight source and the compensation light source. The backlight module includes a compensation light source, and the backlight source and the compensation light source are located at two opposite sides of the accommodation section. The compensation light source may compensate for the illumination light in the light guide plate blocked by the functional module, so as to solve the non-uniform display problem of blocking the illumination light from the backlight source by the functional module.

Abstract: The present invention discloses a core-shell structure supported tungsten composite catalyst and a preparation method and use thereof. Most of the existing synthesis methods of the main ring of quinolone drugs have the defects of many synthesis steps, cumbersome operation, large amount of three wastes, higher costs and the like. The present invention prepares a magnetic separable core-shell supported tungsten composite catalyst, WO3/SiO2/Fe3O4, by preparing Fe3O4 colloid and SiO2/Fe3O4 composite nano-particles. This magnetic separable core-shell supported tungsten composite catalyst, WO3/SiO2/Fe3O4, is used to catalyze and synthesize quinolone compounds. The present invention provides an efficient preparation method of quinolone compounds using a catalyst which can be recovered by magnetic separation and recycled.

Abstract: The present application relates to a display screen, a display device and a method for manufacturing a display screen. The display screen comprises a contour line and an active display region. The active display region includes an edge display region close to the contour line and a main display region away from the contour line. The edge display region and the contour line are intersected. The display screen includes a light-emitting layer and a light-outputting layer having a first region, the first region of the light-outputting layer has a scattering structure provided thereon. Light emitted from the light-emitting layer is deviated from an original propagation direction after passing through the scattering structure. The first region is formed into at least a partial region on the light-outputting layer corresponding to the edge display region.

Abstract: The present disclosure provides a stable solid pharmaceutical dosage form for oral administration. The dosage form includes a substrate that forms at least one compartment and a drug content loaded into the compartment. The dosage form is so designed that the active pharmaceutical ingredient of the drug content is released in a controlled manner.

Abstract: Extracting characteristic information includes receiving a collection command from a client, obtaining, via a collection device, biometric information based on the collection command, selecting a stored extraction algorithm corresponding to the client, the stored extraction algorithm being selected from among a plurality of stored extraction algorithms, extracting characteristic values from the obtained biometric information, the characteristic values being extracted based on the selected extraction algorithm, and sending the extracted characteristic values to the client.